Bilirubin Testing Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

The bilirubin testing market covers in vitro diagnostic assays and devices used to quantify total and direct bilirubin in clinical samples, serving hospitals, diagnostic laboratories, and point-of-care settings. Valued at USD 1.38 billion in 2025, the market is expected to nearly double by 2035 at a steady 6.67% CAGR. Demand is anchored in routine liver function panels, transfusion medicine workups, and universal neonatal jaundice screening protocols in many health systems.

• •Estimated 2025 value of USD 1.38 billion with a 6.67% CAGR projection through 2035.
• •Forecast endpoint of roughly USD 2.6 billion, implying close to a doubling over the period.
• •Core clinical uses include liver function testing, hemolysis assessment, and newborn jaundice screening.

The rising global prevalence of chronic liver disease, viral hepatitis, and alcohol-related liver conditions is increasing the volume of bilirubin tests ordered as part of routine liver panels. At the same time, public-health mandates for universal newborn bilirubin screening before hospital discharge are expanding test volumes in maternity units. Wider installation of automated high-throughput clinical chemistry analyzers, especially in emerging markets, is also making bilirubin testing more accessible and frequent.

• •Growing burden of liver disease and viral hepatitis is lifting test volumes in adult care.
• •Mandatory or recommended neonatal jaundice screening is a structural source of recurring demand.
• •Automation of clinical chemistry platforms is increasing throughput and test adoption in mid-tier laboratories.

The market can be segmented by test type (total bilirubin, direct/conjugated bilirubin, and neonatal transcutaneous measurement), by sample (serum/plasma versus whole blood, including point-of-care capillary testing), and by end user (hospital laboratories, independent diagnostic chains, and home/point-of-care settings). North America holds the leading share, supported by advanced diagnostics infrastructure and universal newborn screening, while Asia-Pacific is the fastest-growing region as China and India scale up lab capacity and maternal-neonatal care programs.

• •Segmentation spans test type, sample method, analyzer modality, and end-user setting.
• •North America leads in revenue, anchored by established newborn screening and clinical chemistry networks.
• •Asia-Pacific is the highest-growth region due to expanding healthcare access and screening mandates.

What are the recent trends and outlook?

A clear trend is the shift toward non-invasive and point-of-care bilirubin testing, particularly transcutaneous meters that reduce blood draws in newborns and shorten clinical decision time. Integration of bilirubin assays into high-throughput automated chemistry platforms and middleware that links results to electronic health records is also accelerating. Over the forecast period, the market is expected to track closely with broader clinical chemistry and IVD growth, supported by aging populations and the continued expansion of newborn screening worldwide.

• •Non-invasive transcutaneous bilirubin testing is gaining share in neonatal care settings.
• •Deeper integration with automated chemistry platforms and EHR-linked middleware is improving lab efficiency.
• •Long-term outlook remains positive, with growth tied to liver disease burden, demographics, and global screening expansion.